<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220961</url>
  </required_header>
  <id_info>
    <org_study_id>02-062A</org_study_id>
    <nct_id>NCT00220961</nct_id>
  </id_info>
  <brief_title>Actos Now for Prevention of Diabetes (ACT NOW)</brief_title>
  <official_title>Actos Now for Prevention of Diabetes (ACT NOW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether pioglitazone versus placebo can reduce the&#xD;
      conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGT is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, the&#xD;
      hyperglycemia-related complications of this devastating disease can be prevented. Subjects&#xD;
      with IGT will be identified with an oral glucose tolerance test (OGTT). Eligible subjects&#xD;
      also will have a measurement of first phase insulin secretion and insulin sensitivity using&#xD;
      the frequently sampled intravenous glucose tolerance test (FSIVGTT) and carotid intimal media&#xD;
      thickness using carotid ultrasound. Following these measurements subjects will be randomized&#xD;
      to receive pioglitazone or placebo and they will return every 3 months for determination of&#xD;
      fasting plasma glucose (FPG) concentration and interim medical history. Recruitment will take&#xD;
      place over 15 months. From the time that the recruitment period ends, subjects will be&#xD;
      followed for a total of 24 months on pioglitazone or placebo. The OGTT will be repeated at&#xD;
      15,27, and 39 months, or if the FPG is â‰¥ 126 mg/dl on the 3-month follow up visits. If the&#xD;
      diagnosis of diabetes is established before month 39 or at month 39, the FSIVGTT and carotid&#xD;
      ultrasound will be repeated. At 39 months, subjects will be washed out of pioglitazone or&#xD;
      placebo and the OGTT, FSIVGTT, and carotid ultrasound will be repeated at month 45.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Type 2 Diabetes</measure>
    <time_frame>2.4 years</time_frame>
    <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Fasting Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atherosclerosis</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>carotid intima thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet similar to pioglitazone tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone tablet similar to placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone tablets - 45 mg/day</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets similar to pioglitazone tablets - 1 tablet/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  All ethnic groups&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and&#xD;
             2 hr glucose of 140-199 mg/dl)&#xD;
&#xD;
          -  At least one of the following:&#xD;
&#xD;
               -  One or more components of the insulin resistance syndrome (HDL &lt; 40 mg/dl in&#xD;
                  females and &lt;35 mg/dl in males, fasting triglycerides &gt; 150 mg/dl, blood pressure&#xD;
                  &gt; 135/85 mmHg, BMI &gt; 24 kg/m2, waist circumference &gt; 102 cm in men and &gt; 88 cm in&#xD;
                  women)&#xD;
&#xD;
               -  One or more first degree relatives with type 2 diabetes&#xD;
&#xD;
               -  History of gestational diabetes&#xD;
&#xD;
               -  Polycystic ovarian disease&#xD;
&#xD;
               -  Minority ethnic background (Mexican American, African American, Asian and Pacific&#xD;
                  Islanders, Native American)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Previously treated with thiazolidinediones (ever) or metformin (within one year)&#xD;
&#xD;
          -  Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor&#xD;
             for more than a week within last year or within the 3 months prior to randomization&#xD;
&#xD;
          -  Previously treated with insulin (other than during pregnancy) for more than one week&#xD;
             within the last year or within the 3 months prior to randomization&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Hospitalization for treatment of heart disease or stroke in past 6 months&#xD;
&#xD;
          -  New York Heart Association Functional Class &gt; 2&#xD;
&#xD;
          -  Left bundle branch block or third degree AV block&#xD;
&#xD;
          -  Aortic stenosis&#xD;
&#xD;
          -  SBP &gt; 180 mmHg or DBP &gt; 105 mmHg&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  GI diseases (pancreatitis, inflammatory bowel disease)&#xD;
&#xD;
          -  Recent or significant abdominal surgery&#xD;
&#xD;
          -  Advanced pulmonary disease&#xD;
&#xD;
          -  Chronic infections&#xD;
&#xD;
          -  Weight loss &gt; 10% in past 6 months&#xD;
&#xD;
          -  Pregnancy and childbearing&#xD;
&#xD;
          -  Major psychiatric disorders&#xD;
&#xD;
          -  Excessive alcohol intake&#xD;
&#xD;
          -  Thiazide use &gt; 25 mg per day&#xD;
&#xD;
          -  Non-selective beta blockers&#xD;
&#xD;
          -  Niacin&#xD;
&#xD;
          -  Systemic glucocorticoids&#xD;
&#xD;
          -  Weight loss or weight gain medication&#xD;
&#xD;
          -  Thyroid disease-suboptimally treated&#xD;
&#xD;
          -  Active endocrine diseases (Cushing's, acromegaly)&#xD;
&#xD;
          -  Plasma triglycerides over 400 mg/dl (despite treatment)&#xD;
&#xD;
          -  History bladder cancer&#xD;
&#xD;
          -  Hematuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A. DeFronzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carl T. Hayden VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC-Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego-San Diego VA Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Health Science Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.org/</url>
    <description>American Diabetes Association</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>June 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2016</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Chief of Diabetes</investigator_title>
  </responsible_party>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Prevention</keyword>
  <keyword>Pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets - 1 tablet/day</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets - 45mg/day tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="0.5"/>
                    <measurement group_id="B2" value="52.3" spread="0.5"/>
                    <measurement group_id="B3" value="52.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevention of Type 2 Diabetes</title>
        <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
        <time_frame>2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Prevention of Type 2 Diabetes</title>
          <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</title>
        <description>Fasting Plasma Glucose</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</title>
          <description>Fasting Plasma Glucose</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.09"/>
                    <measurement group_id="O2" value="-10.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</title>
        <description>Insulin secretion</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</title>
          <description>Insulin secretion</description>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="5"/>
                    <measurement group_id="O2" value="25" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</title>
        <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</title>
          <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
          <units>matsuda index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="3.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atherosclerosis</title>
        <description>carotid intima thickness</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atherosclerosis</title>
          <description>carotid intima thickness</description>
          <units>percentage of intima</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                    <measurement group_id="O2" value="3.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet&#xD;
Placebo: Placebo tablets similar to pioglitazone tablets</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet&#xD;
Pioglitazone: Pioglitazone tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>One unexplained sudden death occurred in the placebo group, and three deaths occurred in the pioglitazone group (one unexplained sudden death, one death from biliary carcinoma, and one death from a carcinoid tumor).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardio infarction, heart failure, other</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="299"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="144" subjects_affected="144" subjects_at_risk="299"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralph DeFronzo, MD</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

